Evaluation of the pharmacological benefit and determination of the influencing factors of intraarterial cis-diamminedichloroplatinum administration in patients with uterine cervical cancer
- PMID: 3664513
Evaluation of the pharmacological benefit and determination of the influencing factors of intraarterial cis-diamminedichloroplatinum administration in patients with uterine cervical cancer
Abstract
cis-Diamminedichloroplatinum (100 mg/m2) was administered to the same patients (n = 9) with advanced uterine cervical tumors, via i.v. and intraarterial (i.a.) (bilateral hypogastric arteries) routes. Measurement of plasma pharmacokinetic parameters enabled us to show up areas under the curve (AUC) of free cis-diamminedichloroplatinum versus time significantly (P less than 0.01) lower after i.a. injection (mean value, 3.9 mg.h/liter) than after i.v. injection (mean value, 5 mg.h/liter). However, the increase in intratumoral concentrations after i.a. administration was only at the limit of statistical significance (P = 0.05). Consequently, the benefit of local i.a. administration, evaluated according to the method of Collins, was small (1.2-2.3). An explanation of the phenomena observed can be given using the generalized compartmental model of Collins. We have demonstrated that the parameters of this model can be entirely calculated by taking into account both the i.v. and i.a. pharmacokinetic measurements. Calculations from experimental data of the model parameters, clearances of the body (ClB), and exchange rate between the site of administration and the rest of the body (Q) were in accordance with the physiological values. On the basis of the parameter values, it was confirmed that the low benefit of i.a. administration was due to the fast blood exchange between the injection site and the rest of the body and the probable cis-diamminedichloroplatinum binding on healthy tissues irrigated by the hypogastric artery.
Similar articles
-
Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical cancer.Int J Clin Pharmacol Res. 2001;21(3-4):105-10. Int J Clin Pharmacol Res. 2001. PMID: 12067139 Clinical Trial.
-
Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II).Cancer Res. 1983 Feb;43(2):917-20. Cancer Res. 1983. PMID: 6681533
-
Comparative study of intravenous and intraarterial cis-platinum on intratumoral platinum concentration in carcinoma of the cervix.Gynecol Oncol. 1989 Feb;32(2):180-3. doi: 10.1016/s0090-8258(89)80030-7. Gynecol Oncol. 1989. PMID: 2910779 Clinical Trial.
-
Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.Semin Oncol. 2000 Feb;27(1 Suppl 1):23-7. Semin Oncol. 2000. PMID: 10697040 Review.
-
Cisplatin pharmacokinetics: applications of a physiological model.Toxicol Lett. 1988 Oct;43(1-3):117-37. doi: 10.1016/0378-4274(88)90024-0. Toxicol Lett. 1988. PMID: 3051521 Review.
Cited by
-
Efficacy of Life Protection Probably from Newly Isolated Bacteria against Cisplatin-Induced Lethal Toxicity.Microorganisms. 2023 Sep 6;11(9):2246. doi: 10.3390/microorganisms11092246. Microorganisms. 2023. PMID: 37764090 Free PMC article.
-
Pharmacokinetics of cisplatin given at a daily low dose as a radiosensitiser.Cancer Chemother Pharmacol. 1990;27(1):55-9. doi: 10.1007/BF00689277. Cancer Chemother Pharmacol. 1990. PMID: 2245493
-
Effect of tumor presence on cisplatin and carboplatin: disposition in the isolated, perfused tumor and skin flap.Cancer Chemother Pharmacol. 1993;32(1):31-8. doi: 10.1007/BF00685873. Cancer Chemother Pharmacol. 1993. PMID: 8462121
-
Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer.Cancer Chemother Pharmacol. 1992;30(3):221-5. doi: 10.1007/BF00686317. Cancer Chemother Pharmacol. 1992. PMID: 1628371
-
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer.Cancer Chemother Pharmacol. 2023 Mar;91(3):247-256. doi: 10.1007/s00280-023-04512-z. Epub 2023 Mar 9. Cancer Chemother Pharmacol. 2023. PMID: 36892677 Free PMC article. Clinical Trial.